PhoreMost Ltd
Building B580, Room 2011
Babraham Research Campus
Babraham
Cambridge
CB22 3AT
United Kingdom
Tel: 44-0-1223-804-163
Website: http://www.phoremost.com/
Email: info@phoremost.com
27 articles about PhoreMost Ltd
-
PhoreMost and ThinkCyte Collaborate to Advance AI-based Drug Discovery
12/13/2022
PhoreMost Ltd. and ThinkCyte K.K. announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence.
-
BioSpace Movers & Shakers, March 4
3/4/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Biopharma and life sciences companies and organizations provide updates on their businesses and pipelines.
-
It takes money to develop new, innovative treatments and this morning, multiple companies have announced significant fundraises. A summary of each financing round is below.
-
XtalPi Invests in Novel Target Discovery Biotech PhoreMost in Oversubscribed Series B Financing
3/23/2021
XtalPi, an artificial intelligence drug discovery and development company, is pleased to announce its investment in the Series B financing of PhoreMost, a UK-based biopharmaceutical company dedicated to 'Drugging the Undruggable®' disease targets.
-
PhoreMost Closes £33M ($46M) Series B Financing
3/23/2021
Dr Catherine Beech appointed Chair and Tim Rea, BGF; Dr Alan Jiang, XtalPi; and Neil Pegg, Morningside Ventures, join Board of Directors
-
BioSpace Global Roundup, Nov. 12
11/12/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
BioSpace Global Roundup, Sept. 10
9/10/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
BioSpace Movers & Shakers: Feb. 7
2/7/2020
Pharma and biotech companies strengthen their leadership teams and boards with this weeks appointments. -
PhoreMost strengthens leadership team with two key appointments
2/3/2020
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has made two appointments to strengthen its leadership team, as the Company positions itself for growth.
-
PhoreMost Enters Multi-Project Drug Discovery Collaboration With Otsuka Pharmaceutical
1/21/2020
PhoreMost’s next-generation phenotypic screening platform, SITESEEKER, to identify novel targets for Otsuka's therapeutics discovery programmes
-
PhoreMost and Otsuka Pharmaceutical Co. entered into a multi-project collaboration to seek out disease-relevant pathways that can be exploited for the development of gene therapies to treat different illnesses.
-
BioSpace Global Roundup, Jan. 9
1/9/2020
Pharma and biotech companies from across the globe provide business and pipeline updates. -
PhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaboration
1/7/2020
PhoreMost to deploy its SITESEEKER platform to identify novel targets for Boehringer Ingelheim's discovery programmes
-
BioSpace Global Roundup, Nov. 7
11/7/2019
Biotech and pharmaceutical companies from across the globe provide updates on their business and pipelines. -
PhoreMost and Sentinel Oncology Expand Collaboration to Jointly Accelerate Novel Glioma Therapeutic Through Preclinical Development
11/4/2019
Lead allosteric PLK1 inhibitor to progress through preclinical and IND enabling studies
-
BioSpace Movers and Shakers, July 19
7/19/2019
Pharma and biotech companies from across the globe expand their leadership teams and boards. -
PhoreMost appoints Dr Lorenz Mayr as Non-Executive Director
7/15/2019
Board appointment will help guide target identification and drug discovery
-
BioSpace Global Roundup, July 11
7/11/2019
Companies from across Europe, Asia and around the globe share pipeline and business updates.